UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Respiratory research, 2024-02, Vol.25 (1)

2024

Volltextzugriff (PDF)

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL)

Expert opinion on drug delivery, 2018-06, Vol.15 (6), p.545-548

2018

Volltextzugriff (PDF)

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Cancer, 2009-02, Vol.115 (3), p.551-560

2009

Volltextzugriff (PDF)

ITEM RESPONSE THEORY (CERAD, CVLT)

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P433-P433

2014

Volltextzugriff (PDF)

P4‐185: UP‐TITRATION TO HIGH‐DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_23), p.P856-P857

2014

Volltextzugriff (PDF)

P1‐329: ITEM RESPONSE THEORY (CERAD, CVLT)

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_11), p.P433-P433

2014

Volltextzugriff (PDF)

UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P856-P857

2014

Volltextzugriff (PDF)

P3–275: Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

Alzheimer's & dementia, 2013-07, Vol.9 (4S_Part_16), p.P656-P657

2013

Volltextzugriff (PDF)

Incidence and predictors of response to the 13.3 (15 cm2 ) and 9.5 mg/24h (10 cm2 ) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P656-P657

2013

Volltextzugriff (PDF)

P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

Alzheimer's & dementia, 2013-07, Vol.9 (4S_Part_16), p.P658-P658

2013

Volltextzugriff (PDF)

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Alzheimer's research & therapy, 2015-03, Vol.7 (1), p.9-9, Article 9

2015

Volltextzugriff (PDF)

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Cancer, 2010-08, Vol.116 (15), p.3750-3750

2010

Volltextzugriff (PDF)

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Blood, 2009-11, Vol.114 (22), p.337-337

2009

Volltextzugriff (PDF)

A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study

Blood, 2008-11, Vol.112 (11), p.335-335

2008

Volltextzugriff (PDF)

Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Blood, 2007-11, Vol.110 (11), p.1047-1047

2007

Volltextzugriff (PDF)

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP)

Blood, 2005-11, Vol.106 (11), p.165-165

2005

Volltextzugriff (PDF)

Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α

Blood, 2005-11, Vol.106 (11), p.1089-1089

2005

Volltextzugriff (PDF)

Classification of Amino-Acid Sequences Using State-Space Models

Between Data Science and Applied Data Analysis, p.615-623

Volltextzugriff (PDF)

Classification of Amino-Acid Sequences Using State-Space Models

Between Data Science and Applied Data Analysis, 2003

2003

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(18)
Buchkapitel
(2)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Thema

Neurology
(3)
Biological And Medical Sciences
(2)
Drug Therapy
(2)
Hematologic And Hematopoietic Diseases
(2)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(2)
Life Sciences & Biomedicine
(2)
Medical Sciences
(2)
Science & Technology
(2)
Activities Of Daily Living
(1)
Adalimumab
(1)
Administration & Dosage
(1)
Alzheimer's Disease
(1)
Analysis
(1)
Autoinjector
(1)
Benzamides
(1)
Bi 695501
(1)
Biosimilar
(1)
Blast
(1)
C-Reactive Protein
(1)
Cancer
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL)

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

ITEM RESPONSE THEORY (CERAD, CVLT)

P4‐185: UP‐TITRATION TO HIGH‐DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

P1‐329: ITEM RESPONSE THEORY (CERAD, CVLT)

UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

P3–275: Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

Incidence and predictors of response to the 13.3 (15 cm2 ) and 9.5 mg/24h (10 cm2 ) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study

P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Commentary

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP)

Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α

Classification of Amino-Acid Sequences Using State-Space Models

Classification of Amino-Acid Sequences Using State-Space Models

Aktive Filter

Suchergebnisse filtern